1993 - Fellow of the American Association for the Advancement of Science (AAAS)
While working on this project, Alexandros Makriyannis studies both Cannabinoid receptor and Cannabinoid receptor type 2. He incorporates Cannabinoid receptor type 2 and Endocannabinoid system in his research. With his scientific publications, his incorporates both Endocannabinoid system and Palmitoylethanolamide. Alexandros Makriyannis connects Palmitoylethanolamide with Fatty acid amide hydrolase in his research. Alexandros Makriyannis performs multidisciplinary studies into Fatty acid amide hydrolase and Cannabinoid in his work. He applies his multidisciplinary studies on Cannabinoid and AM251 in his research. In his papers, he integrates diverse fields, such as AM251 and Cannabinoid receptor. His Internalization research extends to Receptor, which is thematically connected. Much of his study explores Internalization relationship to Receptor.
With his scientific publications, his incorporates both Receptor and Enzyme. He combines Enzyme and Receptor in his studies. He undertakes interdisciplinary study in the fields of Cannabinoid receptor and Cannabinoid receptor antagonist through his research. He combines Cannabinoid receptor antagonist and Cannabinoid in his research. Alexandros Makriyannis undertakes interdisciplinary study in the fields of Cannabinoid and Cannabinoid receptor type 2 through his research. In his works, Alexandros Makriyannis conducts interdisciplinary research on Pharmacology and Neuroscience. He conducts interdisciplinary study in the fields of Neuroscience and Pharmacology through his research. He integrates Biochemistry with Cell biology in his research. Alexandros Makriyannis incorporates Cell biology and Biochemistry in his research.
His Cannabinoid Receptor Agonists research extends to Cannabinoid receptor, which is thematically connected. His research is interdisciplinary, bridging the disciplines of Cannabinoid receptor and Cannabinoid Receptor Agonists. His Receptor study frequently draws connections between adjacent fields such as Serotonin transporter. He performs integrative Serotonin transporter and Serotonin research in his work. Alexandros Makriyannis merges Serotonin with Endocannabinoid system in his research. In his works, Alexandros Makriyannis conducts interdisciplinary research on Endocannabinoid system and Diacylglycerol lipase. His Diacylglycerol lipase study frequently draws connections between related disciplines such as Biochemistry. His Biochemistry study often links to related topics such as Lipase. Alexandros Makriyannis performs multidisciplinary study in Lipase and Monoacylglycerol lipase in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors
Marja D. Van Sickle;Marnie Duncan;Philip J. Kingsley;Abdeslam Mouihate.
Science (2005)
Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition
M. Beltramo;N. Stella;N. Stella;N. Stella;A. Calignano;A. Calignano;A. Calignano;S. Y. Lin;S. Y. Lin;S. Y. Lin.
Science (1997)
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids.
Mohab M. Ibrahim;Frank Porreca;Josephine Lai;Phillip J. Albrecht.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS
Mohab M. Ibrahim;Hongfeng Deng;Alexander Zvonok;Debra A. Cockayne.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists.
Ruoxi Lan;Qian Liu;Pusheng Fan;Sonyuan Lin.
Journal of Medicinal Chemistry (1999)
CB2 cannabinoid receptor-mediated peripheral antinociception.
T.Philip Malan;Mohab M. Ibrahim;Hongfeng Deng;Qian Liu.
Pain (2001)
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity
Joseph Tam;V. Kiran Vemuri;Jie Liu;Sándor Bátkai.
Journal of Clinical Investigation (2010)
Endocannabinoids control spasticity in a multiple sclerosis model
D Baker;G Pryce;J L Croxford;P Brown.
The FASEB Journal (2001)
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
Ruth A Ross;Heather C Brockie;Lesley A Stevenson;Vicki L Murphy.
British Journal of Pharmacology (1999)
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis
Sándor Bátkai;Zoltán Járai;Jens A. Wagner;Sravan K. Goparaju.
Nature Medicine (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Connecticut
University of Hawaii at Manoa
University of Aberdeen
Vanderbilt University
University of California, Irvine
University of Arizona
National Institutes of Health
University of Arizona
University of Calgary
National Institutes of Health
MIT
Duke University
Swiss Federal Laboratories for Materials Science and Technology
Oregon State University
National Institutes of Health
University of Copenhagen
Institut Pasteur
National Cheng Kung University
University of Central Florida
University of Bath
Cornell University
Grenoble Alpes University
University of California, Los Angeles
Peking University
University of Trier
University of Maryland, College Park